Program
PARP1 Inhibitor HRS-1167
Also written as “M9466”, “HRS-1167 tablets” and “HRS-1167”.
Its studies are mostly in Ovarian Neoplasms · Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 33 open or running | phase 2since Feb 26, 2024 | Jul 13, 2022 | Dec 31, 2026phase 1 · NCT05473624 |
| Merck KGaA, Darmstadt, Germany | 31 open or running | phase 1since May 14, 2024 | May 14, 2024 | Feb 22, 2027phase 1 · NCT06421935 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 13, 2022First study: phase 1 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05473624 · 153 planned · China
- Feb 26, 2024Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT06308406 · 54 planned · China
- May 14, 2024Merck KGaA, Darmstadt, Germany’s first study: phase 1 study in Ovarian NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT06421935 · 60 enrolled · United States, Australia, Japan and more
- Jul 15, 2024Phase 1 study in Advanced Solid TumorMerck KGaA, Darmstadt, Germany · NCT06509906 · 3 enrolled · United States, Australia, Japan and more
- Nov 12, 2024Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06689163 · 66 planned · China
- Dec 2, 2024Phase 1 study in Advanced Solid TumorsMerck KGaA, Darmstadt, Germany · NCT06719973
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Advanced Solid TumorsJiangsu HengRui Medicine · NCT05473624
- Feb 22, 2027Primary completion: phase 1 study in Ovarian NeoplasmsMerck KGaA, Darmstadt, Germany · NCT06421935
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06719973Advanced Solid Tumors | 1 | Withdrawn | Merck KGaA, Darmstadt, Germany | May 14, 2025 | 0 |
| NCT06689163Prostatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Nov 30, 2025 | 66 |
| NCT06509906Advanced Solid Tumor · United States, Australia, Japan and more | 1 | Terminated | Merck KGaA, Darmstadt, Germany | Dec 2, 2025 | 3 |
| NCT06421935Ovarian Neoplasms · United States, Australia, Japan and more | 1 | Active, not recruiting | Merck KGaA, Darmstadt, Germany | Feb 22, 2027 | 60 |
| NCT06308406Ovarian Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 2025 | 54 |
| NCT05473624Advanced Solid Tumors · China | 1 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2026 | 153 |
How it is read
Names in the registry
- “M9466”, 3 entries
- “HRS-1167 tablets”, 1 entry
- “HRS-1167”, 1 entry
- “Bevacizumab; HRS-1167”, 1 entry
Codes read as this program: HRS1167.
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.